# Phase 4 hypertension preparation and population exercise

Both comparison records are fresh registry sources. The new draft below is a simulation, with explicitly attributed caller choices rather than an authenticated clinician conversation. The full canonical statements are retained in constructed-canonical-inputs.json; the request/result pairs show what was actually computed.

I PREVENT (NCT00362258) concerns hypertensive people with type 2 diabetes and reports a nonrandomized single-group design. VIOS (NCT00772499) concerns primary hypertension, lists diabetes among exclusions, and reports a randomized parallel comparison of olmesartan-based and atenolol-based regimens. The sample was retained unchanged despite this population difference. These are source descriptions and proposed typed readings, not a claim that the studies are interchangeable comparators.

## Decision list

1. **Should the new population require diabetes?** The first record lists hypertensive type 2 diabetic patients under inclusion; the second lists diabetes under exclusion. Separate source-bound reading calls preserve those typed interpretations as proposed: a quotation that matches the source does not independently establish its normalized meaning. Deliberately supplying a known label in the source template did not promote that reading.

   In the **simulated baseline**, we adopted hypertension, age 35–75 and a population that could qualify through diabetes **or** age 65 or older. Completed checks show both diabetes and its absence are possible under this represented draft. An older, nondiabetic, treatment-naive profile is compatible with those represented restrictions. In the **simulated revision**, we chose to require diabetes. The same nondiabetic profile is then ruled out by that newly adopted population rule. The registry records and their mechanically compiled age facts did not change.

   **Next useful action:** choose whether the study addresses diabetes-associated hypertension, a broader older population or another explicitly defined group. That is a clinical-purpose choice; two sampled records cannot establish a clinical standard.

2. **How should prior treatment and washout interact?** The first record distinguishes newly diagnosed treatment-naive patients from previously treated patients, with further conditions on the latter. The simulated draft preserves an **either/or** structure: treatment-naive **or** previously treated with at most two antihypertensive agents and at least seven days of washout before enrollment. The new construction helpers retain the treatment-history enum, the conjunction within the treated branch, the units, the timing and the caller's attribution in inspectable canonical form.

   A previously treated three-agent profile remains ruled out even when eight days of washout is supplied. That independent answer remains unchanged after revising the diabetes population. More washout does not repair the separate maximum-agent condition.

   This is a partial adoption, not a complete transcription of I PREVENT: its diuretic, achieved-BP, investigator-benefit, glycemic, renal and other conditions remain outside this represented draft. A compatible partial profile must not be described as an eligible patient.

   **Next useful action:** settle those omitted conditions before making a full enrollment decision. If comparing washout durations, keep the same units and time anchor or explicitly supply an accepted conversion premise; the tool did not convert one week to seven days.

3. **Which endpoint and clock fit the new objective?** I PREVENT's BP-control target is distinct from a screening BP limit. VIOS's primary vascular-structure measure at 52weeks is different from I PREVENT's BP target; secondary vascular measurements have additional clocks. We did not make their endpoint definitions equivalent, infer a visit schedule or choose a new-trial target from either record. Neither hypertension record in this pull posts results; that is not evidence of no effect.

   **Next useful action:** choose the intended outcome, define its population/variable and specify the assessment/collection plan before checking dependencies or writing a complete protocol.

4. **How much can a preparation helper confirm?** A default constructed diabetes assertion remained an unconfirmed proposal and was refused as an ordinary premise. A quantity with a boolean operand was refused as malformed. A query using weeks against a days criterion remained unresolved and identified a unit mismatch. These controls preserve useful information without treating an unencoded relation as either true or false.

## Handoff

The managed baseline/revision calls retain full sources, actual child requests/results, origin references, fresh replay and differences. Source children were identical under revision. The new population rule changes the population answer while the separate history exclusion survives. The exact entered statements are inspectable; caller labels still do not independently authenticate their truth or a person's consent.

The clinical work still needed is explicit: agree comparison purpose, choose the population and treatment-history policy, complete the omitted eligibility conditions, and define endpoint/safety/statistical plans. This exercise did not generate a complete protocol, recommend treatment, assess efficacy or calculate biological operating characteristics.
